CS Paper Radar

Evaluating Single and Multi-Omics Based Explainable Artificial Intelligence (MOXAI) for Molecular Subclass Classification of Adult-Type Diffuse Gliomas

Md Zahangir Alom, Quynh T. Tran, Breuer Alexandar, Brent A. Orr

cs.CV cs.AI ·submitted 2026-09-26 03:30 UTC · v1

Abstract

DNA methylation (DNAM) profiling has emerged as a powerful diagnostic tool for classifying brain and solid tumors. However, existing computational models typically analyze methylation and copy number variation (CNV) data separately, failing to capture the complementary information their integration could provide. Moreover, current classification models lack mechanisms for within-class risk assessment analogous to traditional tumor grading, and no established explainability method can attribute classification decisions to specific genomic loci. In this paper, we present MOXAI (Multi-Omics Based Explainable AI), a deep learning framework that integrates DNA methylation and copy number data from methylation arrays to classify molecular subtypes of adult-type diffuse gliomas, alongside single-modality variants for comparison. Using a cohort from The Cancer Genome Atlas (TCGA), we trained ResNet50, DINOv2, and Graph Attention Network (GAT) models on methylation data alone, copy number data alone, and combined multimodal data. We further developed explainable AI (XAI) methods based on class activation maps (CAMs) and gradient-weighted CAM (Grad-CAM) to identify the specific CpG sites, genes, and chromosomal regions most relevant to each classification decision. The multimodal model achieved up to 92.98% cross-validation accuracy, outperforming models trained on CNV data alone. DINOv2 showed the strongest generalization, reaching 94.25% accuracy (confidence >0.9) on independent validation sets. XAI results aligned with established molecular features of adult-type diffuse glioma subtypes, confirming the biological interpretability of the framework.

Comment
8 pages, 6 figures

Closest papers

Nearest neighbours by meaning across the whole index.

A Tumour-Aware Multimodal Framework for Explainable Prediction of IDH Mutation in Gliomas from Multi-Sequence MRI

eess.IV cs.CV ·2026-11-13 ·Tahsien Al-Quraishi, Waseem Alwan Zaboon, O. S. Albahri, Raza Nowrozy
similarity 0.72
Abstract · 45 pages, 12 figures, 4 tables. Preprint of an article submitted for consideration in International Journal of Information Technology & Deci…

Accurate prediction of isocitrate dehydrogenase (IDH) mutation status is essential for glioma diagnosis, prognosis, and treatment planning. Although recent deep learning approaches have demonstrated promising performance, many rely on whole-brain feature extraction and provide limited interpretability. This study proposes a tumour-aware multimodal framework for explainable, non-invasive prediction of IDH mutation status from multiparametric magnetic resonance imaging (MRI). The proposed framework integrates four MRI sequences (T1, T1CE, T2, and FLAIR), tumour subregion segmentation, quantitative radiomic descriptors, and clinical information within a unified deep learning architecture. An ablation study was conducted to evaluate the contribution of tumour-aware learning, radiomic features, and clinical variables. Model performance was assessed using multiple complementary evaluation metrics, including accuracy, precision, recall, F1-score, balanced accuracy, receiver operating characteristic analysis, confusion matrix evaluation, and Grad-CAM visualisation. Experimental results demonstrated that the proposed multimodal framework consistently outperformed the baseline MRI-only model, with the Clinical Fusion model achieving the strongest overall predictive performance. The integration of tumour-aware learning, radiomic descriptors, and clinical information progressively improved classification performance, while Grad-CAM visualisations indicated that the model predominantly focused on biologically relevant tumour regions. These findings suggest that tumour-aware multimodal feature integration enables accurate, interpretable, and non-invasive molecular profiling of gliomas and provides a promising foundation for future clinical decision support in precision neuro-oncology.

0.12

BrainAid: Efficient Brain Tumor Detection Using Lightweight CNNs and Explainable AI for Resource-Constrained Environments

cs.CV ·2026-10-10 ·Sai Sriram Gonthina, Ross Gore, Bikash Chandra Singh, Pronaya Bhattacharya, Sachin Shetty +2 more
similarity 0.71
Abstract

A brain tumor is an unusual growth of cells in the brain that can be cancerous or not, affecting normal brain function and causing serious risk to health. Existing solutions for brain tumor classification, such as expert manual evaluations of magnetic resonance imaging (MRI) scans, are generally inconsistent as different professionals have different criteria and can be resource-intensive, leading to delayed diagnoses. Additionally, while deep learning models have demonstrated potential, they typically require significant computational resources, motivating the need for more efficient and accessible diagnostic tools that can be deployed in real-time healthcare settings. To address these limitations, this study presents BrainAid, which makes efficient use of Convolutional Neural Networks (CNNs) and Vision Transformers (ViTs) for effective classification of four-class classification of glioma, meningioma, pituitary tumor, and no-tumor MRI scans, outperforming all the standard models such as VGG16, Inception-V3, ResNet-50 and so, while integrating Explainable AI (XAI) to improve interpretability. The BrainAid is trained to classify tumors with a high precision of 98%, achieving an F1 score of 98% and an accuracy of 98% using publicly available dataset. The model is deployed on a Raspberry Pi, demonstrating efficiency in low-resource environments. This system shows the feasibility of real-time, edge-based tumor classification, providing quick diagnostic support for medical professionals and enhancing patient care in resource-limited healthcare facilities and underserved areas.

0.07

Enhancing Clinical Classifier Robustness with Deep Representation Learning Based OOD Detection on DNA Methylation Data

cs.AI q-bio.GNcs.LG ·2026-10-26 ·Md Zahangir Alom, Quynh T. Tran, Breuer Alexandar, Brent A. Orr
similarity 0.70
Abstract · 11 pages, 8 figures

DNA methylation (DNAM) array-based tumor classification is a powerful clinical diagnostic tool, but models trained on fixed reference cohorts can produce faulty predictions for tumor types not represented in the training distribution. We propose an end-to-end deep representation learning-based out-of-distribution (OOD) detection framework for DNAm array data. Deep neural network (DNN) classifiers were trained on public sarcoma (SARC) (GSE140686) and brain tumor (BT) (GSE90496) cohorts, and feature vectors were extracted from bottleneck layers. Five OOD methods, including 1dimension (1D)-Subspace Analysis (1D-SSA), K-Nearest Neighbors (KNN), Ridge Regression, Mahalanobis Distance (MD), and Sum of Squared Distances (SSD), were explored with 200 and 500-dimensional embeddings. Spectral discrepancy was used to discriminate in-distribution (IND) from OOD samples. Performance was measured via cross-validation, holdout samples, and an independent clinical dataset. 1D-SSA was the most effective approach. In the sarcoma-IND/brain tumor-OOD setting, the framework achieved an AUROC of 0.975 and True Negative Rate (TNR)@95TPR of 0.930, and an AUROC of 0.9569 and TNR@95TPR of 0.8660 for the brain tumor-IND/sarcoma-OOD setting. On the independent clinical test set, the method yielded a mean AUROC of 0.976, a DE of 0.032, an FPR@95TPR of 0.065, and a TNR@95TPR of 0.935. These results show deep representation-based OOD detection as a practical quality-control layer for clinical-grade methylation-based tumor classification systems.

0.27

An Accurate and Interpretable Hyper Graph Neural Network for GBM Survival Prediction

cs.AI cs.LG ·2026-09-19 ·Mushahid Intesum
position similarity 0.70
Abstract

Survival prediction for glioblastoma multiforme (GBM) demands models that are both accurate and interpretable, yet existing approaches treat these objectives as com- peting, where performant models sacrifice transparency, while interpretable models accept degraded predictive power. We argue that this trade-off is not inherent. Graph neural net- works offer a structural foundation for extracting interpretable, explainable representations without compromising discriminative ability. Furthermore, current methods typically rely on a single imaging modality, underutilizing the complementary information available across multi-modal MRI and clinical metadata. We propose a multi-modal framework that inte- grates three components to address both objectives simultaneously: (1) a sheaf hypergraph neural network that captures higher-order relationships among tissue patches through direc- tional, asymmetric message passing; (2) a concept bottleneck layer that compresses learned representations into clinically grounded concepts, enforcing ante-hoc interpretability; and (3) an extension sufficiency test (EST) regularizer that penalizes unfaithful explanations during training, ensuring that model explanations genuinely reflect the internal decision process. Clinical and genomic features are incorporated through gated fusion, preserving the dominant prognostic signal of molecular markers while retaining concept-level traceabil- ity. Evaluated on 593 patients from the UPenn-GBM dataset under 5-fold cross-validation, our framework achieves a concordance index of 0.643 with the lowest fold-level variance among all compared models (std = 0.015). To our knowledge, this is the first work to unify sheaf hypergraph convolution, concept bottleneck supervision, and EST regularization for interpretable survival prediction from brain MRI

0.19

A Trustworthy Clinical Decision Support Framework for Brain Tumor MRI Classification: Integrating Attention-Guided Learning, Explainable AI, and Out-of-Distribution Validation

cs.CV cs.AIcs.LG ·2026-10-06 ·Arjun Kumar Gupta, Harminder Pal Monga
publishedbenchmark similarity 0.68
Abstract · Accepted for presentation at the IC3AI-2026 IEEE conference in Dec 2026. It has been accepted/selected but is not yet published. 6 pages, 4 …

Deep learning models for brain tumor diagnosis need to do more than achieve high classification accuracy. For practical use, they should also provide understandable predictions, recognize unsuitable inputs, and work within a usable clinical system. This paper presents a framework for classifying brain MRI into four categories: glioma, meningioma, pituitary tumor, and no tumor. The model uses InceptionResNetV2 with a Convolutional Block Attention Module (CBAM), while Grad-CAM provides visual explanations of its predictions. A two-stage out-of-distribution (OOD) mechanism screens unsuitable inputs using an initial grayscale check followed by Mahalanobis distance, softmax confidence, and predictive entropy. These components are brought together in NeuroScan AI, a real-time web application. Evaluated on a Mendeley brain tumor MRI dataset of 12,064 images, the framework achieved 98.70% validation accuracy, 96.73% test accuracy, and a macro-average AUC of 0.9965. The OOD pipeline achieved 99% detection accuracy on a preliminary 100-image benchmark. Grad-CAM visualizations showed qualitative correspondence with clinically established tumor locations across all four classes. Overall, the work brings classification, explainability, input validation, and deployment into one framework, while recognizing that broader clinical and OOD validation is still required.

0.25

Explainable and CPU-Efficient Brain Tumor Classification from MRI Using Two-Phase EfficientNetB3 Fine-Tuning

cs.CV ·2026-11-18 ·Deepro Das, Saad Kabir Uddin, Mohammad Alauddin, Bornali Sarker, Thasnim Akhter
similarity 0.66
Abstract · 6 pages, 5 figures, 6 tables

Brain tumors are among the most lethal neurological disorders, with over 308,000 new diagnoses annually worldwide. Accurate classification of tumor type from Magnetic Resonance Imaging (MRI) scans is critical for treatment planning; however, manual radiological interpretation is time-consuming and prone to inter-observer variability. This paper proposes an automated deep learning pipeline for four-class brain MRI classification (glioma, meningioma, no tumor, and pituitary tumor) using EfficientNetB3 transfer learning with a custom classification head. A two-phase training strategy is adopted: Phase 1 trains the head with a frozen backbone (best validation accuracy: 92.77%), and Phase 2 selectively fine-tunes the top 37 layers at a 100x reduced learning rate (best validation accuracy: 94.91%). On an independent balanced test set of 1,600 MRI images, the system achieves 90.62% overall accuracy and a macro-average AUC of 0.9854. Gradient-weighted Class Activation Mapping (Grad-CAM) is integrated for class-discriminative visual explainability. The proposed system simultaneously addresses three dimensions absent in prior work: high accuracy, CPU-only computational efficiency, and clinical interpretability.

0.14

An Explainable and Scalable Hierarchical Tensor Framework for Integrating Multi-Omics and Digital Pathomics

cs.AI q-bio.GN ·2026-11-19 ·Ahmad Hussein, Ali Anaissi, Mukesh Prasad, Ali Braytee
similarity 0.64
Abstract

Background: Precision oncology requires integration of heterogeneous molecular and pathology data, yet many fusion models offer limited biologically grounded interpretability and struggle with missing modalities. Methods: We present Hierarchical Interpretable Tensor Fusion (HIT-Fuse), integrating six modalities: somatic copy number variation, DNA methylation, RNA sequencing, microRNA expression, RPPA protein abundance, and vision transformer-derived pathomics across four TCGA cohorts (glioma, lung adenocarcinoma, breast, and kidney cancer). Modality-specific autoencoders compress high-dimensional inputs, followed by two-stage CP tensor decomposition. Missing latent modalities are reconstructed using clinical covariates and observed omics to expand cohorts and retrain downstream models. A mathematical traceback mechanism enables global and local xAI attributions. Results: HIT-Fuse identifies distinct latent subgroups with significant survival stratification in glioma, breast, and kidney cohorts, both with complete and reconstructed modalities. Cohort expansion yields cohort-specific gains, including a 56.4% relative increase in weighted F1 for glioma. Biological validation against DepMap CRISPR screens, miRTarBase and RPPA annotations supports decoded drivers across all four cohorts. Essential gene rates range from 6.2% in glioma to 7.6% in lung cancer; example drivers include ANAPC11, SNRPD1, PLK1 and RPL14. Of decoded miRNAs, 71-92% have miRTarBase regulatory support, while 77-84% of selected genes are covered in DepMap. Conclusions: HIT-Fuse combines hierarchical tensor fusion, missing-modality reconstruction and traceable attributions to support interpretable multi-omics and digital pathology-based cancer prognosis across heterogeneous cohorts.

0.06

DNA Methylation Profiling in Melanoma: From Lesion Classification to Therapeutic Stratification

cs.LG q-bio.GN ·2026-08-19 ·Jana T. Winterstein, Lukas Heinlein, Günter Raddatz, Carina Nogueira Garcia, Sarah Haggenmüller +32 more
similarity 0.64
Abstract

DNA methylation provides a stable record of cellular identity, capturing epigenetic programs that distinguish specialized cell states despite a shared genome. Because malignant transformation and tumour progression are accompanied by extensive epigenetic remodeling, we hypothesized that the methylome of melanocytic lesions contains biologically and clinically relevant information for both diagnosis and disease progression. In a cohort of 1,001 tissue samples prospectively collected across eight German university hospitals profiled using Illumina Infinium MethylationEPIC arrays, we compared machine-learning models based on selected Cytosine phosphate Guanine (CpG) methylation sites with models incorporating biology-guided features, including epigenetic age acceleration, cell type composition and copy-number variation burden. In an external test set, the best diagnostic classifier was CpG-based and distinguished melanocytic nevi, noninvasive melanoma and invasive melanoma with a macro-averaged area under the receiver operating characteristic curve of 0.919 (95% CI: 0.878 to 0.952). Notably, across CpGs most strongly hyper- and hypomethylated between NV and IM, NIM showed an intermediate methylation profile, providing a molecular correlate of its diagnostic complexity. The best model for clinically relevant treatment group prediction, with AJCC stages grouped according to guideline-based management recommendations, relied on biology-guided features and achieved a macro-averaged mean absolute error of 0.627 (95% CI: 0.477 to 0.808). Together, these findings demonstrate that methylation-based models can capture both diagnostic identity and clinically relevant disease stratification, supporting DNA methylation as a promising biomarker for further validation and potential clinical translation.

0.26